vs

Side-by-side financial comparison of Cellectis S.A. (CLLS) and Virginia National Bankshares Corp (VABK). Click either name above to swap in a different company.

Virginia National Bankshares Corp is the larger business by last-quarter revenue ($15.0M vs $9.5M, roughly 1.6× Cellectis S.A.). Virginia National Bankshares Corp runs the higher net margin — 39.7% vs -265.9%, a 305.6% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs 3.6%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $20.8M).

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

United Bankshares, Inc. is a bank holding company dual-headquartered in Charleston, West Virginia and Fairfax, Virginia with operations in West Virginia, Virginia, the District of Columbia, Maryland, Ohio, Pennsylvania, North Carolina, South Carolina, and Georgia in the United States. United Bankshares is the parent company of United Bank which comprises nearly 250 offices in eight states. In addition, UBSI is the parent company to subsidiaries George Mason Mortgage, United Brokerage, and Cre...

CLLS vs VABK — Head-to-Head

Bigger by revenue
VABK
VABK
1.6× larger
VABK
$15.0M
$9.5M
CLLS
Growing faster (revenue YoY)
CLLS
CLLS
+371.4% gap
CLLS
375.0%
3.6%
VABK
Higher net margin
VABK
VABK
305.6% more per $
VABK
39.7%
-265.9%
CLLS
More free cash flow
CLLS
CLLS
$6.9M more FCF
CLLS
$27.6M
$20.8M
VABK

Income Statement — Q2 FY2024 vs Q4 FY2025

Metric
CLLS
CLLS
VABK
VABK
Revenue
$9.5M
$15.0M
Net Profit
$-25.3M
$6.0M
Gross Margin
Operating Margin
-181.1%
50.5%
Net Margin
-265.9%
39.7%
Revenue YoY
375.0%
3.6%
Net Profit YoY
-51.9%
30.6%
EPS (diluted)
$-0.28
$1.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLLS
CLLS
VABK
VABK
Q4 25
$15.0M
Q3 25
$14.4M
Q2 25
$14.1M
Q1 25
$14.1M
Q4 24
$14.5M
Q3 24
$13.5M
Q2 24
$9.5M
$12.9M
Q1 24
$13.1M
Net Profit
CLLS
CLLS
VABK
VABK
Q4 25
$6.0M
Q3 25
$4.6M
Q2 25
$4.2M
Q1 25
$4.5M
Q4 24
$4.6M
Q3 24
$4.6M
Q2 24
$-25.3M
$4.2M
Q1 24
$3.6M
Operating Margin
CLLS
CLLS
VABK
VABK
Q4 25
50.5%
Q3 25
39.4%
Q2 25
38.4%
Q1 25
38.4%
Q4 24
40.3%
Q3 24
41.9%
Q2 24
-181.1%
39.5%
Q1 24
32.9%
Net Margin
CLLS
CLLS
VABK
VABK
Q4 25
39.7%
Q3 25
31.7%
Q2 25
30.0%
Q1 25
31.9%
Q4 24
31.4%
Q3 24
34.1%
Q2 24
-265.9%
32.3%
Q1 24
27.8%
EPS (diluted)
CLLS
CLLS
VABK
VABK
Q4 25
$1.10
Q3 25
$0.84
Q2 25
$0.78
Q1 25
$0.83
Q4 24
$0.85
Q3 24
$0.85
Q2 24
$-0.28
$0.77
Q1 24
$0.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLLS
CLLS
VABK
VABK
Cash + ST InvestmentsLiquidity on hand
$149.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$148.6M
$184.2M
Total Assets
$407.1M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLLS
CLLS
VABK
VABK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$149.0M
Q1 24
Stockholders' Equity
CLLS
CLLS
VABK
VABK
Q4 25
$184.2M
Q3 25
$177.4M
Q2 25
$170.8M
Q1 25
$166.8M
Q4 24
$160.3M
Q3 24
$165.9M
Q2 24
$148.6M
$154.2M
Q1 24
$152.6M
Total Assets
CLLS
CLLS
VABK
VABK
Q4 25
$1.6B
Q3 25
$1.6B
Q2 25
$1.6B
Q1 25
$1.6B
Q4 24
$1.6B
Q3 24
$1.6B
Q2 24
$407.1M
$1.6B
Q1 24
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLLS
CLLS
VABK
VABK
Operating Cash FlowLast quarter
$28.9M
$21.3M
Free Cash FlowOCF − Capex
$27.6M
$20.8M
FCF MarginFCF / Revenue
290.5%
138.2%
Capex IntensityCapex / Revenue
13.2%
3.9%
Cash ConversionOCF / Net Profit
3.58×
TTM Free Cash FlowTrailing 4 quarters
$35.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLLS
CLLS
VABK
VABK
Q4 25
$21.3M
Q3 25
$6.0M
Q2 25
$6.7M
Q1 25
$2.1M
Q4 24
$15.3M
Q3 24
$15.2M
Q2 24
$28.9M
$-6.4M
Q1 24
$3.2M
Free Cash Flow
CLLS
CLLS
VABK
VABK
Q4 25
$20.8M
Q3 25
$5.9M
Q2 25
$6.7M
Q1 25
$1.8M
Q4 24
$14.6M
Q3 24
$15.1M
Q2 24
$27.6M
$-6.8M
Q1 24
$3.1M
FCF Margin
CLLS
CLLS
VABK
VABK
Q4 25
138.2%
Q3 25
41.0%
Q2 25
47.6%
Q1 25
13.0%
Q4 24
100.4%
Q3 24
111.7%
Q2 24
290.5%
-53.0%
Q1 24
23.9%
Capex Intensity
CLLS
CLLS
VABK
VABK
Q4 25
3.9%
Q3 25
0.5%
Q2 25
0.2%
Q1 25
1.8%
Q4 24
5.1%
Q3 24
0.9%
Q2 24
13.2%
3.1%
Q1 24
0.2%
Cash Conversion
CLLS
CLLS
VABK
VABK
Q4 25
3.58×
Q3 25
1.31×
Q2 25
1.59×
Q1 25
0.47×
Q4 24
3.35×
Q3 24
3.30×
Q2 24
-1.54×
Q1 24
0.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons